petition from t315i patients on the web, page-4

biotek,

Explain why Hospira kicked in $18M with a further potenital $120M not including royalities. They have also chipped in development and research costs to develop Omapro further.

All this for just CML patients minus US market?

I think you will find that the 200 figure is pa not total patients.

Also, the reason why Omaparo results for multiple TKIs are not as high as other treatments is because these patients have ALREADY failed those treatments that you mentioned.

The fact that Omapro is achieving any indications on this patient population is a great result.

To compare apples with apples, Omapro will need to conduct a trial as a 1st line therapy, i.e. no other previous TKI treatment undertaken by patients.